Table 2

Clinical and mycological outcome and safety of treatment of 11 neonates with amphotericin B lipid complex (ABLC)

Patient no	Prior antifungals	Duration of prior antifungals (days)	Average ABLC dose (mg/kg/day)	Duration of ABLC (days)	Pretreatment creatinine (μmol/l)	Post-treatment creatinine (μmol/l)	Mycological outcome	Clinical outcome
1		Amphotericin	14	4.7		7		80	97	Eradicated	Failure
		5FC	10
		Rifampin	7
2		Amphotericin	24	5.0		23		35	35	NE, ABLC sustained eradication	Success
		5FC	24
3		Amphotericin	56	5.4		14		35	35	NE, ABLC sustained eradication	Success
		5FC	35
		Rifampin	18
4		Amphotericin	13 (QOD)	5.0		25		88^2-150	150^2-150	Eradicated	Success
		5FC	7
5	Amphotericin	18	6.5	28	88	44	Eradicated	Success
6		Amphotericin	7	3.2		30		141	18	Eradicated	Success
		5FC	1
7	Amphotericin	17	4.1	41	44	35	Eradicated	Success
8	Amphotericin	2	4.8	14	522	628	Eradicated	Success
9		Amphotericin	30	5.6		17		35	44	Eradicated	Success
		5FC	1
		Fluconazole	12
10		Amphotericin	19	6.2		29		35	26	Eradicated	Success
		5FC	12
11		Amphotericin	1	3.9		4		168^2-150	221^2-150	Persisted	Failure
		Fluconazole	3